<DOC>
	<DOC>NCT01608841</DOC>
	<brief_summary>The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.</brief_summary>
	<brief_title>The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib</brief_title>
	<detailed_description>The influence of EGFR mutations on the efficacy of treatment with and without erlotinib in metastatic pancreatic cancer is to be determined.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>metastatic chemotherapyna√Øve pancreatic cancer patients histologically confirmed adequate samples for analysis Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2 absolute neutrophil count (ANC) &gt;= 1,500/mm3 platelet count &gt;= 100,000/mm3 serum creatinine &lt;= 1.5 mg/dL aspartate aminotransferase (AST) alanine aminotransferase (ALT) &lt; 5 times the upper limit of normal absence of any other malignancy or serious medical or psychological illness that would preclude informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>